IRIS - Res&Arch Institutional Research Information System - Research & Archive

PACIOTTI, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.069
EU - Europa 956
AS - Asia 252
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.279
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.067
IT - Italia 268
IE - Irlanda 250
FR - Francia 108
HK - Hong Kong 100
UA - Ucraina 76
CN - Cina 72
VN - Vietnam 67
RO - Romania 49
SE - Svezia 44
FI - Finlandia 38
RU - Federazione Russa 36
DE - Germania 35
BE - Belgio 13
GB - Regno Unito 11
TR - Turchia 8
CH - Svizzera 7
GR - Grecia 6
AT - Austria 5
NL - Olanda 5
PL - Polonia 3
SG - Singapore 3
MX - Messico 2
AU - Australia 1
CZ - Repubblica Ceca 1
EU - Europa 1
JP - Giappone 1
NO - Norvegia 1
UZ - Uzbekistan 1
Totale 2.279
Salva come PNG Salva come JPEG
Città #
Chandler 276
Dublin 250
Perugia 156
San Mateo 104
Hong Kong 100
Ann Arbor 68
Dong Ket 67
Altamura 59
Beijing 54
Bucharest 49
Wilmington 46
Medford 44
Princeton 44
Jacksonville 38
Lawrence 38
Ashburn 28
Des Moines 27
Andover 26
Redmond 21
Helsinki 15
Brussels 13
Saint Petersburg 13
Los Angeles 10
Redwood City 10
Norwalk 8
Houston 7
Izmir 7
San Paolo di Civitate 7
Seattle 6
Woodbridge 6
Fairfield 5
Falls Church 5
Chicago 4
Milan 4
Boardman 3
Cambridge 3
Den Haag 3
Florence 3
Moscow 3
Assisi 2
Lappeenranta 2
Lausanne 2
Rome 2
Spoleto 2
Vienna 2
Aksaray 1
Amsterdam 1
Bergen 1
Changsha 1
Ergolding 1
Esslingen am Neckar 1
Frankfurt Am Main 1
Gunzenhausen 1
Irakleio 1
Melbourne 1
Mexico City 1
Monmouth Junction 1
Napoli 1
New York 1
Oleggio 1
Parabiago 1
Queens 1
Radeberg 1
Simi Valley 1
Singapore 1
Tappahannock 1
Tokyo 1
Wageningen 1
Zero Branco 1
Totale 1.666
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 111
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration 101
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients 87
Accumulation of free oligosaccharides and tissue damage in cytosolic alpha-mannosidase (Man2c1)-deficient mice. 85
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 74
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies 73
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies 68
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease 65
Lysosomal alpha-mannosidase and alpha-mannosidosis 64
null 63
Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. 62
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 62
Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies 61
di-N-acetylchitobiase-deficient mice accumulate Man2GlcNAc2 and Man3GlcNAc2 59
Lysosomal enzymes in Parkinson's disease 58
Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. 57
Free oligosaccharides accumulation and tissue damages in Ma2c1 deficient mice 57
Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids 57
Identification of two novel beta-mannosidosis-associated sequence variants: biochemical analysis of beta mannosidase (MANBA) missense mutations. 56
Lysosomal di-N-acetylchitobiase-deficient mouse tissues accumulate Man2GlcNAc2 and Man3GlcNAc2 53
Generation of a chitobiase knock out mouse model 52
The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction 52
Are we ready for detecting α-synuclein prone to aggregation in patients? The case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as diagnostic tools 50
Novel CSF biomarkers to discriminate FTLD and its pathological subtypes 50
Molecular cloning and structural organization of the gene encoding the mouse lysosomal di-N-acetylchitobiase (ctbs) 48
Biochemical analysis of missense mutations in beta-mannosidosis 47
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 46
Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links 44
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 44
Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma 43
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis 43
Next generation sequencing applications in agro biotechnology 42
Fingerprinting Alzheimer's Disease by 1H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid 42
Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid. 41
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 41
Emerging therapies and therapeutic concepts for lysosomal storage diseases 38
Origin of α-mannosidase activity in CSF 38
Parkinson's and Lewy body dementia CSF biomarkers 37
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease 35
Dopamine-dependent early synaptic and motor dysfunctions induced by a-synuclein in the nigrostriatal circuit 33
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease 32
Role of Lysosomal Enzymes in Parkinson’s Disease: Lesson from Gaucher’s Disease 29
Lysosomal enzymes in PD: further evidence is needed. 29
Interlaboratory proficiency processing scheme in CSF aliquoting: Implementation and assessment based on biomarkers of Alzheimer's disease 29
First pilot newborn screening for our lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene 29
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 20
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 10
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 10
Totale 2.427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.823
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 0 7 0
2019/2020275 22 11 18 2 27 2 46 20 15 46 26 40
2020/2021341 7 18 2 20 99 9 23 11 33 16 21 82
2021/2022504 16 78 7 11 7 19 6 107 37 51 74 91
2022/2023867 51 162 15 75 66 97 0 34 324 1 31 11
2023/2024224 27 28 25 6 2 1 75 14 20 14 12 0
Totale 2.427